The Gene Regulation Program Area is composed of 21 members, spanning 8 Departments within UCLA. In ;he past competing cycle, investigators from this Program authored 374 publications, of which 94 (25%) were nter-programmatic and 15 (4%) intra-programmatic. 155 (41%) were placed in high-impact journals. 15 members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $12.2 million in total costs, including $1.6 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the GR Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the GR Program Area total $832,185. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. The Gene Regulation Program Area is completing its first full CCSG cycle. The initial goal of the Program Area was to bring together the strong existing group of gene regulation researchers at UCLA and to develop a collective interest in the application of gene regulation studies to problems of cancer origin, development, and therapy. The original group of 12 has grown to 21 members, in large part by recruitment of a group of extraordinary young investigators as Assistant Professors. Substantial investment by the JCCC, the DGSoM, and the College of Letters and Science has benefited this Program Area enormously. During the current CCSG cycle, we have focused on four major objectives: (1) to promote among our members the study of fundamental mechanisms of gene regulation, using appropriate model organisms, mammalian cells, and animal models;(2) to study the molecular/transcriptional mechanisms that mediate cell differentiation, nflammation and viral latency and investigate how aberrations in these processes affect cancer initiation and progression;(3) to serve as a resource for the other Program Areas in the JCCC in the use of gene regulation concepts and methodologies to advance their research problems;and (4) to promote the translation of existing knowledge and new discoveries into translational and clinical applications. Interactions among members are fostered by a monthly meeting, a weekly journal club, and a seminar series that brings "leaders in the field" to UCLA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-38
Application #
8392126
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$140,572
Indirect Cost
$66,161
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications